Uploaded November 2024 | Updated September 2026, 1 week ago
UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at the university in early 2024. The treatment, known as E-SYNC, is a form of “switchable” CAR-T therapy that can be turned on and off to better target cancer and reduce side effects. It was designed by UCSF Professor of Neurological Surgery, Surgery and Immunology Hideho Okada, MD, PhD, and Professor of Cellular and Molecular Pharmacology Wendell Lim, PhD. Lim is also the director of UCSF’s Cell Design Institute.
Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain cancer glioblastoma.
Read more:
https://www.ucsf.edu/news/2024/11/428776/how-switchable-car-t-therapy-sets-its-sights-deadly-brain-cancer
UC San Francisco treated its first brain cancer patient with an experimental new CAR-T therapy discovered and manufactured at the university in early 2024. The treatment, known as E-SYNC, is a form of “switchable” CAR-T therapy that can be turned on and off to better target cancer and reduce side effects. It was designed by UCSF Professor of Neurological Surgery, Surgery and Immunology Hideho Okada, MD, PhD, and Professor of Cellular and Molecular Pharmacology Wendell Lim, PhD. Lim is also the director of UCSF’s Cell Design Institute.
Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain cancer glioblastoma.
Read more:
https://www.ucsf.edu/news/2024/11/428776/how-switchable-car-t-therapy-sets-its-sights-deadly-brain-cancer
